Newsroom

NYB AI is featured in Tech in Asia for pioneering AI-driven drug discovery in Southeast Asia.

NYB AI is featured in The Business Times for transforming drug discovery in Southeast Asia with its AI platform, DTIGN.

Nanyang Biologics (NYB) made a strong presence at COMPUTEX 2025, one of the world's premier technology exhibitions, held from May 20–23 at the Taipei Nangang Exhibition Center. The event, themed "AI Next," brought together global leaders in artificial intelligence, robotics, and next-generation technologies who are driving the future of innovation.

Nanyang Biologics (NYB) and Precisya Global Inc. (PGI) have partnered to combine AI-powered compound discovery with advanced genetic risk profiling - bringing a new dimension to precision health through nature-derived interventions.

Nanyang Biologics will be joining GITEX ASIA – Asia’s largest and most global tech, startup, and digital investment event – taking place from April 23 to 25 at Marina Bay Sands, Singapore.

A pioneering collaboration with Nanyang Technological University Singapore with the NYB - NTU Joint Laboratory, aiming at revolutionizing drug discovery through the power of AI and natural compounds.

Nanyang Biologics is revolutionizing drug discovery with AI at NVIDIA GTC 2025! Discover how we’re using the latest technologies to accelerate life-saving innovations.

Advancing Bioactivity Prediction Through Molecular Docking and Self-Attention.

Nanyang Biologics' AI-driven DTIGN platform revolutionizes natural compound drug discovery with great accuracy, efficiency, and speed, unlocking nature's vast therapeutic potential for breakthrough treatments.

Nanyang Biologics becomes a resident company of JLABS, joining a global network dedicated to accelerating life-enhancing health and wellness solutions.

Nanyang Biologics harnesses NVIDIA AI and accelerated computing to transform $7 billion drug discovery industry.